𝔖 Bobbio Scriptorium
✦   LIBER   ✦

rViscumin, a novel anticancer agent — preclinical and clinical development status

✍ Scribed by K. Wilhelm-Ogunbiyi; B. Möckel; A. Burger; M. Langer; H. Zinke; H.H. Fiebig; H. Lentzen

Book ID
117657704
Publisher
Elsevier Science
Year
2001
Tongue
English
Weight
96 KB
Volume
37
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

KP1019, A New Redox-Active Anticancer Ag
KP1019, A New Redox-Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
✍ Christian G. Hartinger; Michael A. Jakupec; Stefanie Zorbas-Seifried; Michael Gr 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB 👁 1 views

## Abstract The promising drug candidate indazolium __trans__‐[tetrachlorobis(1__H__‐indazole)ruthenate(III)] (KP1019) is the second Ru‐based anticancer agent to enter clinical trials. In this review, which is an update of a paper from 2006 (__Hartinger et al., J. Inorg. Biochem.__ **2006**, __100_

ChemInform Abstract: KP1019, A New Redox
ChemInform Abstract: KP1019, A New Redox-Active Anticancer Agent — Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
✍ Christian G. Hartinger; Michael A. Jakupec; Stefanie Zorbas-Seifried; Michael Gr 📂 Article 📅 2009 🏛 John Wiley and Sons ⚖ 16 KB 👁 1 views

## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable v